Search

Author/Creator van Vollenhoven, R F

1. Biologics use in sle in 23 centers – data from the international registry for biologics in SLE. (22nd February 2012)

Authors:
van Vollenhoven, R F; Jacobsen, Søren; Wallace, Daniel; Hanly, John G; Petri, Michelle; Isenberg, David A; Clarke, Ann E; Pineau, Christian A; Bernatsky, Sasha; Simard, Julia F; Bae, Sang-Cheol; Ramos-Casals, Manuel; Díaz-Lagares, Cándido; Ruiz-Irastorza, Guillermo; Martínez-Berriotxoa, Agustín; ...
Journal:
Annals of the rheumatic diseases
Issue:
Volume 71(2012)Supplement 1
Page Start:
A9
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Issue 6 (6th May 2010)

Authors:
Nam, J L; Winthrop, K L; van Vollenhoven, R F; Pavelka, K; Valesini, G; Hensor, E M A; Worthy, G; Landewé, R; Smolen, J S; Emery, P; Buch, M H
Journal:
Annals of the rheumatic diseases
Issue:
Volume 69:Issue 6(2010)
Page Start:
976
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Dysregulated Fcγ receptor IIa-induced cytokine production in dendritic cells of lupus nephritis patients. (7th October 2019)

Authors:
Newling, M; Fiechter, R H; Sritharan, L; Hoepel, W; van Burgsteden, J A; Hak, A E; van Vollenhoven, R F; van de Sande, M G H; Baeten, D L P; den Dunnen, J
Journal:
Clinical and experimental immunology
Issue:
Volume 199:Number 1(2020)
Page Start:
39
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Issue 2 (7th October 2009)

Authors:
Van den Bosch, F; Manger, B; Goupille, P; McHugh, N; Rødevand, E; Holck, P; van Vollenhoven, R F; Leirisalo-Repo, M; FitzGerald, O; Kron, M; Frank, M; Kary, S; Kupper, H
Journal:
Annals of the rheumatic diseases
Issue:
Volume 69:Issue 2(2010)
Page Start:
394
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Issue 6 (17th November 2008)

Authors:
Fleischmann, R; Vencovsky, J; van Vollenhoven, R F; Borenstein, D; Box, J; Coteur, G; Goel, N; Brezinschek, H-P; Innes, A; Strand, V
Journal:
Annals of the rheumatic diseases
Issue:
Volume 68:Issue 6(2009)
Page Start:
805
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Issue 6 (17th November 2008)

Authors:
Smolen, J; Landewé, R B; Mease, P; Brzezicki, J; Mason, D; Luijtens, K; van Vollenhoven, R F; Kavanaugh, A; Schiff, M; Burmester, G R; Strand, V; Vencovský, J; van der Heijde, D
Journal:
Annals of the rheumatic diseases
Issue:
Volume 68:Issue 6(2009)
Page Start:
797
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Issue 2 (20th August 2015)

Authors:
Merrill, J T; van Vollenhoven, R F; Buyon, J P; Furie, R A; Stohl, W; Morgan-Cox, M; Dickson, C; Anderson, P W; Lee, C; Berclaz, P-Y; Dörner, T
Journal:
Annals of the rheumatic diseases
Issue:
Volume 75:Issue 2(2016)
Page Start:
332
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗